{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T19:33:01Z","timestamp":1792611181534,"version":"4.5.0"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,12,1]],"date-time":"2019-12-01T00:00:00Z","timestamp":1575158400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,12,1]],"date-time":"2020-12-01T00:00:00Z","timestamp":1606780800000},"content-version":"vor","delay-in-days":366,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100014588","name":"Sanofi Pasteur","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014588","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["valuehealthregionalissues.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Value in Health Regional Issues"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1016\/j.vhri.2019.01.004","type":"journal-article","created":{"date-parts":[[2019,4,8]],"date-time":"2019-04-08T17:38:39Z","timestamp":1554745119000},"page":"60-65","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia"],"prefix":"10.1016","volume":"20","author":[{"given":"Alexia","family":"Kieffer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Celine","family":"Hoestlandt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yaneth","family":"Gil-Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Broban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilo","family":"Casta\u00f1eda-Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diego","family":"Rosselli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vhri.2019.01.004_bib1","first-page":"219","article-title":"Stability of yellow fever vaccine","volume":"87","author":"Monath","year":"1996","journal-title":"Dev Biol Stand"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.004_bib2","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.cll.2010.01.001","article-title":"Yellow fever: a reemerging threat","volume":"30","author":"Gardner","year":"2010","journal-title":"Clin Lab Med"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.004_bib3","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1007\/s11908-996-0005-9","article-title":"Current assessment of yellow fever and yellow fever vaccine","volume":"6","author":"Lefeuvre","year":"2004","journal-title":"Curr Infect Dis Rep"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.004_bib4","doi-asserted-by":"crossref","first-page":"126","DOI":"10.4161\/hv.26549","article-title":"Yellow fever vaccine: an effective vaccine for travelers","volume":"10","author":"Verma","year":"2014","journal-title":"Hum Vaccin Immunother"},{"issue":"4","key":"10.1016\/j.vhri.2019.01.004_bib5","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1586\/14760584.3.4.413","article-title":"Current status of the Arilvax: yellow fever vaccine","volume":"3","author":"Barrett","year":"2004","journal-title":"Expert Rev Vaccines"},{"issue":"35","key":"10.1016\/j.vhri.2019.01.004_bib6","doi-asserted-by":"crossref","first-page":"4261","DOI":"10.1016\/j.vaccine.2015.03.077","article-title":"An inactivated yellow fever 17DD vaccine cultivated in Vero cell cultures","volume":"33","author":"Pereira","year":"2015","journal-title":"Vaccine"},{"issue":"RR-7","key":"10.1016\/j.vhri.2019.01.004_bib7","first-page":"1","article-title":"Yellow fever vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP)","volume":"59","author":"Staples","year":"2010","journal-title":"MMWR Recomm Rep"},{"issue":"21","key":"10.1016\/j.vhri.2019.01.004_bib8","doi-asserted-by":"crossref","first-page":"3180","DOI":"10.1016\/j.vaccine.2012.03.003","article-title":"A small animal peripheral challenge model of yellow fever using interferon-receptor deficient mice and the 17D-204 vaccine strain","volume":"30","author":"Thibodeaux","year":"2012","journal-title":"Vaccine"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.004_bib9","first-page":"CD010929","article-title":"Yellow fever vaccine for patients with HIV infection","author":"Barte","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"19","key":"10.1016\/j.vhri.2019.01.004_bib10","first-page":"806","article-title":"Preparation of the yellow fever vaccine produced by the Pasteur Institute, Dakar","volume":"2","year":"1946","journal-title":"Wkly Bull Epidemiol Inf Receiv"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.004_bib11","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1084\/jem.20041526","article-title":"Yellow fever 17D as a vaccine vector for microbial CTL epitopes: protection in a rodent malaria model","volume":"201","author":"Tao","year":"2005","journal-title":"J Exp Med"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.004_bib12","doi-asserted-by":"crossref","first-page":"359","DOI":"10.4269\/ajtmh.2012.11-0525","article-title":"The safety of yellow fever vaccine 17D or 17DD in children, pregnant women, HIV+ individuals, and older persons: systematic review","volume":"86","author":"Thomas","year":"2012","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vhri.2019.01.004_bib13","first-page":"473170","article-title":"Occurrence of autoimmune diseases related to the vaccine against yellow fever","volume":"2014","author":"Oliveira","year":"2014","journal-title":"Autoimmune Dis"},{"issue":"3","key":"10.1016\/j.vhri.2019.01.004_bib14","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11908-017-0566-9","article-title":"Live attenuated yellow fever 17D vaccine: a legacy vaccine still controlling outbreaks in modern day","volume":"19","author":"Collins","year":"2017","journal-title":"Curr Infect Dis Rep"},{"key":"10.1016\/j.vhri.2019.01.004_bib15","series-title":"Vacuna contra fiebre amarilla","year":"2017"},{"key":"10.1016\/j.vhri.2019.01.004_bib16","series-title":"Tropical DI","article-title":"Epidemiologie de la Fievre Jaune, Amerique du Sud 19 fevrier 2008","year":"2008"},{"key":"10.1016\/j.vhri.2019.01.004_bib21","first-page":"16","article-title":"Manual para la elaboraci\u00f3n de evaluaciones econ\u00f3micas","year":"2014","journal-title":"Bogota"},{"key":"10.1016\/j.vhri.2019.01.004_bib23","unstructured":"PIB. Metodolog\u00eda a\u00f1o base 2005. Banco de la Rep\u00fablica (banco central de Colombia). http:\/\/www.banrep.gov.co\/es\/pib. Accessed May 12, 2017."},{"key":"10.1016\/j.vhri.2019.01.004_bib26","series-title":"Lineamientos T\u00e9cnicos y Operativos para la universalizaci\u00f3n de la vacuna contra el Neumococo en el Esquema del Programa Ampliado de Inmunizaciones Colombia","year":"2011"},{"key":"10.1016\/j.vhri.2019.01.004_bib27","doi-asserted-by":"crossref","first-page":"C72","DOI":"10.1016\/j.vaccine.2013.05.038","article-title":"Using standardized tools to improve immunization costing data for program planning: the cost of the Colombian expanded program on immunization","volume":"31","author":"Castaneda-Orjuela","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vhri.2019.01.004_bib29","series-title":"WHO District Guidelines for Yellow Fever Surveillance","year":"2000"},{"key":"10.1016\/j.vhri.2019.01.004_bib30","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jcv.2014.08.030","article-title":"Yellow fever","volume":"64","author":"Monath","year":"2015","journal-title":"J Clin Virol"},{"issue":"5","key":"10.1016\/j.vhri.2019.01.004_bib31","doi-asserted-by":"crossref","first-page":"e1001638","DOI":"10.1371\/journal.pmed.1001638","article-title":"Yellow fever in Africa: estimating the burden of disease and impact of mass vaccination from outbreak and serological data","volume":"11","author":"Garske","year":"2014","journal-title":"PLoS Med"},{"key":"10.1016\/j.vhri.2019.01.004_bib32","series-title":"SISMED\u2014Sistema de informaci\u00f3n de precios de medicamentos","year":"2016"},{"key":"10.1016\/j.vhri.2019.01.004_bib33","series-title":"Manual de tarifas de la Entidad Promotora de Salud","year":"2001"},{"key":"10.1016\/j.vhri.2019.01.004_bib36","series-title":"WHO Methods and Data Sources for Global Burden of Disease Estimates 2000-2015","year":"2017"},{"issue":"1","key":"10.1016\/j.vhri.2019.01.004_bib37","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1478-7954-9-1","article-title":"Measuring the burden of arboviral diseases: the spectrum of morbidity and mortality from four prevalent infections","volume":"9","author":"Labeaud","year":"2011","journal-title":"Popul Health Metr"},{"issue":"39\/40","key":"10.1016\/j.vhri.2019.01.004_bib38","doi-asserted-by":"crossref","first-page":"6945","DOI":"10.1016\/j.vaccine.2007.06.065","article-title":"An economic evaluation of thermostable vaccines in Cambodia, Ghana and Bangladesh","volume":"25","author":"Levin","year":"2007","journal-title":"Vaccine"},{"issue":"2","key":"10.1016\/j.vhri.2019.01.004_bib39","doi-asserted-by":"crossref","first-page":"274","DOI":"10.4269\/ajtmh.1993.48.274","article-title":"Should yellow fever vaccine be included in the expanded program of immunization in Africa? A cost-effectiveness analysis for Nigeria","volume":"48","author":"Monath","year":"1993","journal-title":"Am J Trop Med Hyg"},{"issue":"4","key":"10.1016\/j.vhri.2019.01.004_bib40","first-page":"383","article-title":"Estimated operational costs of vaccination campaign to combat yellow fever in Abidjan","volume":"21","author":"Zengbe-Acray","year":"2009","journal-title":"Sante Publique"},{"issue":"suppl 1","key":"10.1016\/j.vhri.2019.01.004_bib41","first-page":"52","article-title":"Trends in yellow fever mortality in Colombia, 1998-2009","volume":"33","author":"Segura","year":"2013","journal-title":"Biomedica"},{"key":"10.1016\/j.vhri.2019.01.004_bib42","series-title":"Revision of the International Health Regulations Geneva","year":"2005"},{"issue":"27","key":"10.1016\/j.vhri.2019.01.004_bib43","first-page":"269","article-title":"Vaccines and vaccination against yellow fever. WHO position paper\u2014June 2013","volume":"88","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vhri.2019.01.004_bib44","series-title":"Global Strategy to Eliminate Yellow Fever Epidemics (EYE)","first-page":"1","year":"2016"}],"container-title":["Value in Health Regional Issues"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210991930038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221210991930038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T20:11:36Z","timestamp":1761941496000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221210991930038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,12]]},"references-count":34,"alternative-id":["S221210991930038X"],"URL":"https:\/\/doi.org\/10.1016\/j.vhri.2019.01.004","relation":{},"ISSN":["2212-1099"],"issn-type":[{"value":"2212-1099","type":"print"}],"subject":[],"published":{"date-parts":[[2019,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Public Health Benefits and Economic Value of Routine Yellow Fever Vaccination in Colombia","name":"articletitle","label":"Article Title"},{"value":"Value in Health Regional Issues","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vhri.2019.01.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 ISPOR--The professional society for health economics and outcomes research. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}